Getting medicines into brain neurons without using viruses
Enhancing Non-Viral Neuron-Specific Molecule Delivery Across Species in the CNS
Using a small neuron-targeting peptide to carry drugs and proteins directly into nerve cells to help people with brain disorders.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Dallas NIH-funded |
| Lab location | 1 site (Richardson, United States) |
| Project ID | NIH-11311370 on NIH RePORTER |
What this research studies
This project develops and tests a 15-amino-acid peptide called N1 that selectively binds to neurons and can attach to different drugs, proteins, and chemicals. Researchers will measure what sizes and types of molecules N1 can carry into neurons in cells and animal models from multiple species and will study how N1 finds and enters neurons. The team will optimize the peptide’s stability and delivery methods, including efforts toward non-invasive delivery into the brain. Findings will guide whether the approach can be adapted for human tissues and future clinical testing.
Who could benefit from this research
Good fit: People with neurological conditions that could benefit from neuron-targeted therapies—such as certain neurodegenerative or focal brain disorders—could be future candidates for trials based on this work.
Not a fit: Patients with conditions not involving the brain, or those needing immediate standard-of-care treatments, are unlikely to gain direct benefit from this preclinical research in the near term.
Why it matters
Potential benefit: If successful, this could enable safer, more precise delivery of therapies into neurons without viral vectors, opening new treatment options for neurological conditions.
How similar studies have performed: Related non-viral neuron-targeting methods have shown promise in laboratory and animal studies but remain largely unproven in humans, and the N1 peptide represents a novel, early-stage approach with encouraging preclinical data.
Where this research is happening
Richardson, United States
- University of Texas Dallas — Richardson, United States (Active)
Researchers
- Principal investigator: Qin, Zhenpeng — University of Texas Dallas
- Study coordinator: Qin, Zhenpeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.